Informations générales (source: ClinicalTrials.gov)
A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Interventional
Phase 1
Bristol-Myers Squibb (Voir sur ClinicalTrials)
janvier 2026
avril 2031
11 juin 2026
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell
Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if
BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Christophe MASSARD | 15/06/2026 08:35:04 | Contacter | ||
Critères
Tous
- Participants must have histologically confirmed diagnosis of locally advanced or
metastatic ccRCC.
- For part 1: Participants must have already had at least two different treatment
plans in the past, including immunotherapy and a targeted therapy.
- For part 2: Participants must have had at least one standard treatment plan that
included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the
other).
- Participants must have Eastern Cooperative Oncology Group (ECOG) performance status
of 0 to 1.
Exclusion Criteria:
- Participants with Inability to administer and/or tolerate oral medication without
chewing, breaking, crushing, or otherwise altering the product dosage form.
- For Part 2A: Participants who have received more than 3 prior systemic regimens for
locally advanced or metastatic ccRCC including prior treatment with HIF2a
inhibitors.
- Participants who have hypoxia as defined by a pulse oximeter reading < 92% at rest
or requires intermittent or chronic supplemental oxygen.
- Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or
recombinant EPO) within 28 days prior to the first dose of study intervention.
- Other protocol-defined Inclusion/Exclusion criteria apply.